News

On the basis of discovery into what drives adult-onset eczema, the novel drug may provide a unique benefit for impacted patients.

A post hoc analysis shows the investigative drug significantly improved atopic dermatitis symptoms versus placebo as soon as the first week into a phase 2 trial.

In research presented at the 2023 SDPA summer conference, new pharmacovigilance data over a 4-year span aligned with the established safety profile on brodalumab.

It's been a whirlwind few years for dermatology. The nurse practitioner discusses modern care teams, comorbid psoriatic disease, and expanding patient inclusion in clinical trials.

The treatment, developed by Intercept Pharmaceuticals, could not be approved in its present form, according to the CRL and any resubmission of the treatment for patients with NASH would require at least the successful completion of the long-term outcomes phase of the REGENERATE study.

In this interview segment, Dr. Barbieri explained the major takeaways from his conference talk on acne and rosacea with a focus on the more severe levels of these conditions.

The results show 55.4% of patients in the ketamine group had a response, compared to 41.2% of patients in the ECT group.

In this conference interview, Dr. Barbieri described some of the major takeaways from his talk on foundational tools for patients with acne and rosacea.

During this conference talk, Dr. Nicole Gunasekera spoke about options for acne scar treatments such as chemical peels and microneedling, as well as special considerations for richly-pigmented skin.

Yan discusses how acne care strategies have been bolstered—and complicated—by pharmacotherapy and telemedicine developments.

With multiple drug classes working toward FDA indication, a dermatologists explains his strategy for managing hidradenitis suppurativa.

Findings show patients hospitalized for COVID-19 have an increased 1-year risk of venous thromboembolic disease compared with those hospitalized for influenza (HR, 1.77; 95% CI, 1.36-2.31).

The first trial observing the topical drug in children held promise for an extended indication.

The CHOP pediatric dermatology director reviews recent breakthroughs in understanding complex pathophysiology of skin diseases.

The investigator explains why he believes the PDE4 inhibitor is "as close to a perfect drug as you can hope for in seborrheic dermatitis."

The analysis of 2021 data show lung cancer screening rates increased 8.4% since 2019 to 21.2%.

Patients with high attendance rates within the lifestyle intervention group lost more weight than those with medium and low rates.

Patients with anxiety or depression who engaged in health-related social media usage were significantly more likely to report to report intentions to quit smoking, endorse past 12-month attempts at smoking cessation, and were more likely to meet national recommendation for weekly strength training.

A randomized trial assessing a telehealth intervention suggest such an intervention could improve quality of life among people undergoing dialysis.

A meta-analysis of 13 trials suggests SGLT2 inhibitors reduced heart failure events and cardiovascular death across these patient populations, with consistent effects in patients with varying disease combinations.

A systematic review and meta-analysis found no significant differences in visual and anatomical outcomes between ranibizumab biosimilars and reference ranibizumab in eyes with neovascular AMD.

According to investigators, this is among the largest studies describing the risk of bacteremia in young patients with sickle cell disease.

These new findings suggest the need for expansion of JAK1/JAK2 targeting approaches for treatment of eosinophilic cellulitis and other types of eosinophilic disease.

An analysis of data from the NYC A1C Registry suggests women with gestational diabetes were more likely to develop diabetes after giving birth and were also more likely to have difficulty achieving glycemic control after diagnosis.

The results show high centrality of anxiety and depression in patients with COVID-19 and anxiety had the highest bridge influence in the network.

This new data emphasizes the vital importance of timely detection and effective treatment for squamous cell carcinomas in this particular population.

After making adjustments, the results show a positive association between alcohol dependence at 18 years and depression at age 24 years. However, there was no association between the rate of change and depression.

The rituximab biosimilar rixathon was linked to the the lowest average annual cost per patient across 6 indications among all biosimilars.